Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVP-923 for Levodopa-induced Dyskinesia in Parkinson's Disease
NCT01767129Phase 2Completed
- Sponsor
- Avanir Pharmaceuticals
- Start
- Oct 2013
- Primary completion
- Feb 2015
- Modality
- Classical Binding Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of dextromethorphan + quinidine in levodopa-induced dyskinesia (LID), sponsored by Avanir Pharmaceuticals. Started Oct 2013; status: completed.
02
Drugs
dextromethorphan + quinidine
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT01767129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01767129.